GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (FRA:Q9T) » Definitions » Other Gross PPE

ME Therapeutics Holding (FRA:Q9T) Other Gross PPE : €0.18 Mil (As of Feb. 2025)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Other Gross PPE?

ME Therapeutics Holding's Other Gross PPE for the quarter that ended in Feb. 2025 was €0.18 Mil.

ME Therapeutics Holding's quarterly Other Gross PPE declined from Aug. 2024 (€0.00 Mil) to Nov. 2024 (€-0.00 Mil) but then increased from Nov. 2024 (€-0.00 Mil) to Feb. 2025 (€0.18 Mil).


ME Therapeutics Holding Other Gross PPE Historical Data

The historical data trend for ME Therapeutics Holding's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Other Gross PPE Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23 Aug24
Other Gross PPE
- - -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.18

ME Therapeutics Holding Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


ME Therapeutics Holding Business Description

Traded in Other Exchanges
Address
177 Robson St., Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding Headlines

No Headlines